Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure

William T. Abraham, Koonlawee Nademanee, Kent Volosin, Steven Krueger, Suresh Neelagaru, Nirav Raval, Owen Obel, Stanislav Weiner, Marc Wish, Peter Carson, Kenneth Ellenbogen, Robert Bourge, Michael K. Parides, Richard P. Chiacchierini, Rochelle Goldsmith, Sidney Goldstein, Yuval Mika, Daniel Burkhoff, Alan Kadish

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the absolute refractory period intended to improve contraction. We previously tested the safety and efficacy of CCM in 428 NYHA functional class III/IV heart failure patients with EF ≤35% and narrow QRS randomized to optimal medical treatment (OMT) plus CCM (n = 215) versus OMT alone (n = 213) and found no significant effect on ventilatory anaerobic threshold (VAT), the study's primary end point. In the present analysis, we sought to identify if there was a subgroup of patients who showed a response to CCM. Methods and Results: The protocol specified that multiregression analysis would be used to determine if baseline EF, NYHA functional class, pVO 2, or etiology of heart failure influenced the impact of CCM on AT. Etiology and baseline pVO 2 did not affect efficacy. However, baseline NYHA functional class III and EF ≥25% were significant predictors of increased efficacy. In this subgroup (comprising 97 OMT and 109 CCM patients, ∼48% of the entire population) VAT increased by 0.10 ± 2.36 in CCM versus -0.54 ± 1.83 mL kg -1 min -1 in OMT (P =.03) and pVO 2 increased by 0.34 ± 3.11 in CCM versus -0.97 ± 2.31 (P =.001) at 24 weeks compared with baseline; 44% of CCM versus 23% of OMT subjects showed improvement of ≥1 class in NYHA functional class (P =.002), and 59% of CCM versus 42% of OMT subjects showed a ≥10-point reduction in Minnesota Living with Heart Failure Questionnaire (P =.01). All of these findings were similar to those seen at 50 weeks. Conclusions: The results of this retrospective hypothesis-generating analysis indicate that CCM significantly improves objective parameters of exercise tolerance in a subgroup of patients characterized by normal QRS duration, NYHA functional class III symptoms, and EF >25%.

Original languageEnglish (US)
Pages (from-to)710-717
Number of pages8
JournalJournal of Cardiac Failure
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Randomized Controlled Trials
Heart Failure
Safety
Anaerobic Threshold
Therapeutics
Exercise Tolerance
Population

Keywords

  • Cardiac contractility modulation
  • cardiopulmonary stress testing
  • Minnesota Living With Heart Failure Questionnaire
  • New York Heart Failure Classification six minute hall walk test
  • peak VO
  • ventilatory anaerobic threshold

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. / Abraham, William T.; Nademanee, Koonlawee; Volosin, Kent; Krueger, Steven; Neelagaru, Suresh; Raval, Nirav; Obel, Owen; Weiner, Stanislav; Wish, Marc; Carson, Peter; Ellenbogen, Kenneth; Bourge, Robert; Parides, Michael K.; Chiacchierini, Richard P.; Goldsmith, Rochelle; Goldstein, Sidney; Mika, Yuval; Burkhoff, Daniel; Kadish, Alan.

In: Journal of Cardiac Failure, Vol. 17, No. 9, 01.09.2011, p. 710-717.

Research output: Contribution to journalArticle

Abraham, WT, Nademanee, K, Volosin, K, Krueger, S, Neelagaru, S, Raval, N, Obel, O, Weiner, S, Wish, M, Carson, P, Ellenbogen, K, Bourge, R, Parides, MK, Chiacchierini, RP, Goldsmith, R, Goldstein, S, Mika, Y, Burkhoff, D & Kadish, A 2011, 'Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure', Journal of Cardiac Failure, vol. 17, no. 9, pp. 710-717. https://doi.org/10.1016/j.cardfail.2011.05.006
Abraham, William T. ; Nademanee, Koonlawee ; Volosin, Kent ; Krueger, Steven ; Neelagaru, Suresh ; Raval, Nirav ; Obel, Owen ; Weiner, Stanislav ; Wish, Marc ; Carson, Peter ; Ellenbogen, Kenneth ; Bourge, Robert ; Parides, Michael K. ; Chiacchierini, Richard P. ; Goldsmith, Rochelle ; Goldstein, Sidney ; Mika, Yuval ; Burkhoff, Daniel ; Kadish, Alan. / Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. In: Journal of Cardiac Failure. 2011 ; Vol. 17, No. 9. pp. 710-717.
@article{fcfa9f0c76364f1fbdf75a2d2ca60815,
title = "Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure",
abstract = "Background: Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the absolute refractory period intended to improve contraction. We previously tested the safety and efficacy of CCM in 428 NYHA functional class III/IV heart failure patients with EF ≤35{\%} and narrow QRS randomized to optimal medical treatment (OMT) plus CCM (n = 215) versus OMT alone (n = 213) and found no significant effect on ventilatory anaerobic threshold (VAT), the study's primary end point. In the present analysis, we sought to identify if there was a subgroup of patients who showed a response to CCM. Methods and Results: The protocol specified that multiregression analysis would be used to determine if baseline EF, NYHA functional class, pVO 2, or etiology of heart failure influenced the impact of CCM on AT. Etiology and baseline pVO 2 did not affect efficacy. However, baseline NYHA functional class III and EF ≥25{\%} were significant predictors of increased efficacy. In this subgroup (comprising 97 OMT and 109 CCM patients, ∼48{\%} of the entire population) VAT increased by 0.10 ± 2.36 in CCM versus -0.54 ± 1.83 mL kg -1 min -1 in OMT (P =.03) and pVO 2 increased by 0.34 ± 3.11 in CCM versus -0.97 ± 2.31 (P =.001) at 24 weeks compared with baseline; 44{\%} of CCM versus 23{\%} of OMT subjects showed improvement of ≥1 class in NYHA functional class (P =.002), and 59{\%} of CCM versus 42{\%} of OMT subjects showed a ≥10-point reduction in Minnesota Living with Heart Failure Questionnaire (P =.01). All of these findings were similar to those seen at 50 weeks. Conclusions: The results of this retrospective hypothesis-generating analysis indicate that CCM significantly improves objective parameters of exercise tolerance in a subgroup of patients characterized by normal QRS duration, NYHA functional class III symptoms, and EF >25{\%}.",
keywords = "Cardiac contractility modulation, cardiopulmonary stress testing, Minnesota Living With Heart Failure Questionnaire, New York Heart Failure Classification six minute hall walk test, peak VO, ventilatory anaerobic threshold",
author = "Abraham, {William T.} and Koonlawee Nademanee and Kent Volosin and Steven Krueger and Suresh Neelagaru and Nirav Raval and Owen Obel and Stanislav Weiner and Marc Wish and Peter Carson and Kenneth Ellenbogen and Robert Bourge and Parides, {Michael K.} and Chiacchierini, {Richard P.} and Rochelle Goldsmith and Sidney Goldstein and Yuval Mika and Daniel Burkhoff and Alan Kadish",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.cardfail.2011.05.006",
language = "English (US)",
volume = "17",
pages = "710--717",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "9",

}

TY - JOUR

T1 - Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure

AU - Abraham, William T.

AU - Nademanee, Koonlawee

AU - Volosin, Kent

AU - Krueger, Steven

AU - Neelagaru, Suresh

AU - Raval, Nirav

AU - Obel, Owen

AU - Weiner, Stanislav

AU - Wish, Marc

AU - Carson, Peter

AU - Ellenbogen, Kenneth

AU - Bourge, Robert

AU - Parides, Michael K.

AU - Chiacchierini, Richard P.

AU - Goldsmith, Rochelle

AU - Goldstein, Sidney

AU - Mika, Yuval

AU - Burkhoff, Daniel

AU - Kadish, Alan

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the absolute refractory period intended to improve contraction. We previously tested the safety and efficacy of CCM in 428 NYHA functional class III/IV heart failure patients with EF ≤35% and narrow QRS randomized to optimal medical treatment (OMT) plus CCM (n = 215) versus OMT alone (n = 213) and found no significant effect on ventilatory anaerobic threshold (VAT), the study's primary end point. In the present analysis, we sought to identify if there was a subgroup of patients who showed a response to CCM. Methods and Results: The protocol specified that multiregression analysis would be used to determine if baseline EF, NYHA functional class, pVO 2, or etiology of heart failure influenced the impact of CCM on AT. Etiology and baseline pVO 2 did not affect efficacy. However, baseline NYHA functional class III and EF ≥25% were significant predictors of increased efficacy. In this subgroup (comprising 97 OMT and 109 CCM patients, ∼48% of the entire population) VAT increased by 0.10 ± 2.36 in CCM versus -0.54 ± 1.83 mL kg -1 min -1 in OMT (P =.03) and pVO 2 increased by 0.34 ± 3.11 in CCM versus -0.97 ± 2.31 (P =.001) at 24 weeks compared with baseline; 44% of CCM versus 23% of OMT subjects showed improvement of ≥1 class in NYHA functional class (P =.002), and 59% of CCM versus 42% of OMT subjects showed a ≥10-point reduction in Minnesota Living with Heart Failure Questionnaire (P =.01). All of these findings were similar to those seen at 50 weeks. Conclusions: The results of this retrospective hypothesis-generating analysis indicate that CCM significantly improves objective parameters of exercise tolerance in a subgroup of patients characterized by normal QRS duration, NYHA functional class III symptoms, and EF >25%.

AB - Background: Cardiac contractility modulation (CCM) signals are nonexcitatory electrical signals delivered during the absolute refractory period intended to improve contraction. We previously tested the safety and efficacy of CCM in 428 NYHA functional class III/IV heart failure patients with EF ≤35% and narrow QRS randomized to optimal medical treatment (OMT) plus CCM (n = 215) versus OMT alone (n = 213) and found no significant effect on ventilatory anaerobic threshold (VAT), the study's primary end point. In the present analysis, we sought to identify if there was a subgroup of patients who showed a response to CCM. Methods and Results: The protocol specified that multiregression analysis would be used to determine if baseline EF, NYHA functional class, pVO 2, or etiology of heart failure influenced the impact of CCM on AT. Etiology and baseline pVO 2 did not affect efficacy. However, baseline NYHA functional class III and EF ≥25% were significant predictors of increased efficacy. In this subgroup (comprising 97 OMT and 109 CCM patients, ∼48% of the entire population) VAT increased by 0.10 ± 2.36 in CCM versus -0.54 ± 1.83 mL kg -1 min -1 in OMT (P =.03) and pVO 2 increased by 0.34 ± 3.11 in CCM versus -0.97 ± 2.31 (P =.001) at 24 weeks compared with baseline; 44% of CCM versus 23% of OMT subjects showed improvement of ≥1 class in NYHA functional class (P =.002), and 59% of CCM versus 42% of OMT subjects showed a ≥10-point reduction in Minnesota Living with Heart Failure Questionnaire (P =.01). All of these findings were similar to those seen at 50 weeks. Conclusions: The results of this retrospective hypothesis-generating analysis indicate that CCM significantly improves objective parameters of exercise tolerance in a subgroup of patients characterized by normal QRS duration, NYHA functional class III symptoms, and EF >25%.

KW - Cardiac contractility modulation

KW - cardiopulmonary stress testing

KW - Minnesota Living With Heart Failure Questionnaire

KW - New York Heart Failure Classification six minute hall walk test

KW - peak VO

KW - ventilatory anaerobic threshold

UR - http://www.scopus.com/inward/record.url?scp=80052269340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052269340&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2011.05.006

DO - 10.1016/j.cardfail.2011.05.006

M3 - Article

C2 - 21872139

AN - SCOPUS:80052269340

VL - 17

SP - 710

EP - 717

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 9

ER -